Tumor Immunology and Immunotherapy

Sunday, October 1  

Monday, October 2 

Tuesday, October 3

Wednesday, October 4


Sunday, October 1

Welcome and Opening Keynotes  and Special Lecture
6:00 p.m.-8:30 p.m.

Principles of response and resistance to immunotherapy
Levi A. Garraway, Eli Lilly and Company, Indianapolis, Indiana

Engineering T cells to eradicate tumors in the age of synthetic biology
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, Washington

Immune checkpoint blockade in cancer therapy: New insights, opportunities, and prospects for cures
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, Texas 

Welcome Reception
8:00 p.m.-10:0​0 p.m.

Monday, October 2 

Breakfast and Networking Roundtables

7:00 a.m.-8:15​ a.m.

Plenary Session 1: Single Cell Imaging of Cancer Immunology
Session Chair: Matthew F. Krummel, University of California San Franciscot, San Francisco, California  
8:15​ a.m.-9:45 a.m.

Pathology from the molecular scale on up
Garry P. Nolan, Stanford University, Stanford, California

Tracking immune cells in sterile injury and how it pertains to cancer
Paul Kubes, University of Calgary, Calgary, Canada

Imaging- and single cell- based insights into effective anti-tumor immune responses
Matthew F. Krummel​

9:45 a.m.-10:15 a.m.

Plenary Session 2: Synthetic Immunotherapy
Session Chair: ​Darrell J. Irvine, Koch Institute For Integrative Cancer Research at MIT, Cambridge, Massachusetts
10:15 a.m.-12:15 p.m.

Enhancing combination immunotherapy and adoptive cell therapy of cancer via lymph node-targeted vaccines
Darrell J. Irvine

Genetic engineering of therapeutic T cells using synthetic nanoparticles
Matthias T. Stephan, Fred Hutchinson Cancer Research Center, Seattle, Washington

Engineering T cells to resist and convert immunosuppressive tumor microenvironments
Yvonne Y. Chen, University of California Los Angeles, Los Angeles, California

Targeting multiple myeloma with universal SLAMF7-specific CAR T-cells*
Rohit Mathur, The University of Texas MD Anderson Cancer Center, Houston, Texas 

 Lunch on Own
12:15 p.m.-1:30 p.m.

Plenary Session 3: Neoantigens: The New Biomarkers
Session Chair: Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts
1:30 p.m.-3:15 p.m.

RiboSeq and ye shall find: Non-canonical protein translation in cancer immunosurveillance

Jonathan W. Yewdell, National Institute of Allergy and Infectious Diseases, Rockville, Maryland

Cell Transfer Immunotherapy Targeting Unique Somatic Mutations in Cancer

Steven A. Rosenberg, National Cancer Institute, Bethesda, Maryland

Developing and improving personalized neoantigen-targeting cancer vaccines

Catherine J. Wu

Identification of breast cancer neoantigens exposed by radiation therapy*
Claire Lhuillier, Weill Cornell Medical College, New York, New York 

3:15 p.m.-3:45 p.m.

Plenary Session 4: A Systems Approach to Immuno-Oncology
Session Chair: Dana Pe’er, Sloan Kettering Institute​​, New York, New York  
3:45 p.m.-5:30 p.m.

Integrative genomics and immune contexture approach to immuno-oncology
Jerome Galon, INSERM UMR 1138, Cordeliers Research Center, Paris, France

Spatio-temporal quirks of IFN-γ regulation of immune responses in tumors
Gregoire Altan-Bonnet, National Cancer Institute, Bethesda, Maryland

An Atlas of the Tumor Immune Ecosystem
Dana Pe’er

Genetic mechanisms of immune evasion in colorectal cancer* Marios Giannakis, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 

Poster Session A / Reception
5:30 p.m.-7:30 p.m.

Top of page

Tuesday, October 3      

Breakfast and Networking Roundtables
7:00 a.m.-8:00 a.m.

Plenary Session 5:
The Inflammatory Tumor Microenvironment 
Session Chair: Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York
8:00 a.m.-9:45 a.m.

Immune cell atlas of human lung cancer lesions
Miriam Merad

Macrophages orchestrate early dissemination and metastasis.
Julio A. Aguirre-Ghiso, Icahn School of Medicine at Mount Sinai, New York, New York  

Stromal microenvironments in cancer immunology
Shannon J. Turley, Genentech, Inc., San Francisco, California

Lymph node colonization promotes systemic tumor metastasis through induction of immune tolerance*
Nathan E. Reticker-Flynn, Stanford University, Stanford, California 

Preventing the recurrence of breast cancer at the metastatic niche using resolution-phase macrophages*
Dalit Barkan, University of Haifa, Haifa, Israel

9:45 a.m.-10:15 a.m.

Plenary Session 6: Engineering Immune Cells to Treat Cancer
Session Chair: Carl H. June, University of Pennsylvania, Philadelphia, Pennsylvania
10:15 a.m.-12:00 p.m.

CAR therapy: beyond the CD19 paradigm
Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, New York

New directions in T cell therapies for cancer
Marcela V. Maus, Massachusetts General Hospital, Cancer Center, Boston, Massachusetts

Updates on CAR T Cells
Carl H. June

Poster Session B / Lunch
12:00 p.m.-2:30 p.m.

Plenary Session 7: The Microbiome in Cancer Immunity 
Session Chair: Giorgio Trinchieri, National Cancer Institute, Bethesda, Maryland
2:30 p.m.-4:30 p.m.

Cancer and the microbiome
Giorgio Trinchieri

Fusobacterium nucleatum and colon cancer
Wendy Garrett, Harvard T.H. Chan School of Public Health, Cambridge, Massachusetts

Understanding response and resistance to cancer therapy: Lessons learned from melanoma
Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas

Drugging the human microbiome for combination with tumor immunotherapy*
David N. Cook, Seres Therapeutics, Cambridge, Massachusetts

Fusobacterium species, microsatellite instability, and exome-wide neoantigen load in relation to immune response to colorectal cancer*
Shuji Ogino, Brigham and Women’s Hospital, Boston, Massachusetts 

4:30 p.m.-4:45 p.m.

Plenary Session 8: Metabolic Regulation of Immune Responses
Session Chair: Luke A. J. O’Neill, Trinity College Dublin, Dublin, Ireland​
​4:45 p.m.-6:30 p.m.

Krebs cycle reprogrammed for cytokines
Luke A. O’Neill

Identification of essential genes for cancer immunotherapy
Nicholas P. Restifo, National Cancer Institute, Bethesda, Maryland 

Immunometabolic circuits in myeloid cell reprogramming
Mihai Netea, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands

Metabolic adaptations establish immunotherapy resistance in melanoma*
Ashvin R. Jaiswal, The University of Texas MD Anderson Cancer Center, Houston, Texas 

Top of page

Wednesday, October 4

Continental Breakfast
7:00 a.m.-8:00 a.m.

Plenary Session 9: New Combination Therapies
Session Chair: ​Sandra Demaria, Weill Cornell Medical College, New York, New York
8:00 a.m.-9:45 a.m.

Strategies to optimize the adjuvant role of radiotherapy during cancer immunotherapy
Silvia C. Formenti, Weill Cornell Medicine, New York, New York

Cancer Immunotherapy: Translational Control of Immune Checkpoint
Caroline Robert, Institut de Cancerologie Gustave Roussy, Villejuif, France

Novel insights into the dose-dependency of radiation immunogenicity
Sandra Demaria

Breaking down barriers restricting myeloid cell differentiation and infiltration in the tumor microenvironment with a first-in-class antibody targeting semaphorin4D, and rational combination therapies*
 Elizabeth E. Evans, Vaccinex, Rochester, New York

9:45 a.m.-10:15 a.m.

Plenary Session 10: Checkpoints and Immunomodulation
Session Chair: Joshua D. Brody, Icahn School of Medicine at Mount Sinai, New York, New York
10:15 a.m.-11:30 a.m.      

Regulatory T Cells and Radiation Therapy
Charles G. Drake, Columbia University Medical Center, New York, New York​                      

Improving Checkpoint Blockade for Lymphoma with Flt3L-Primed In Situ Vaccination
Joshua D. Brody, Icahn School of Medicine at Mount Sinai, New York, New York

Cancer-germline antigens discriminate clinical outcome to CTLA4 blockade*
 Sachet Shukla, Dana-Farber Cancer Institute, Boston, Massachusetts 

Closing Remarks and Departure
11:30 a.m. a.m.

*Short talk from proffered abstract

Top of page